

Supplement 5. Sensitivity analyses.

Primary VF	STATA NMA	Ranking	Sensitivity	Ranking	ADDIS NMA	Ranking
Zoledronic acid	0.23(0.05,1.06)	1	0.29(0.15,0.57)	1	0.21 (0.02,1.71)	2
Risedronate	2.47(0.09,69.00)	4	0.37(0.20,0.72)	4	NA*	4
Alendronate	0.22(0.03,1.55)	2	0.33(0.15,0.70)	2	0.19 (0.01,1.84)	1
Ibandronate	0.26(0.02,4.25)	3	0.26(0.02,3.00)	3	0.21 (0.00,7.86)	3
GIOP VF	STATA NMA		Sensitivity	Ranking	ADDIS NMA	Ranking
Zoledronic acid	0.34(0.02,5.34)	2	NA	NA	0.32 (0.01,25.03)	2
Risedronate	0.15(0.04,0.58)	1	NA	NA	0.12 (0.01,0.99)	1
Alendronate	0.60(0.04,9.82)	3	NA	NA	0.62 (0.01,39.20)	3
Primary NVF	STATA NMA		Sensitivity	Ranking	ADDIS NMA	Ranking
Zoledronic acid	NA §	NA §	0.65(0.21,1.99)	2	0.62 (0.11,3.37)	2
Risedronate	NA §	NA §	0.50(0.29,0.86)	1	0.53 (0.10,2.99)	1
Alendronate	NA §	NA §	0.77(0.23,2.60)	3	0.78 (0.13,4.65)	3
Ibandronate	NA §	NA §	2.26(0.10,51.19)	4	NA*	4

NA: Not available

§ Results from frequentist model is not available since data is too sparse to estimate heterogeneity.

*: Unstable data with 0 event happen when performing network meta-analysis using Bayesian model.